Delivering therapeutics to the central nervous system (CNS) remains one of the greatest challenges in neurodegeneration treatment. The blood-brain barrier (BBB) restricts approximately 98% of small molecule drugs and nearly all large molecule biologics from entering the brain parenchyma. This page provides a comprehensive overview of current and emerging CNS drug delivery strategies, their mechanisms, clinical applications, and future directions. [@finkel2017]
For detailed information on BBB biology and structure, see Blood-Brain Barrier Biology. [@mercuri2018]
Intrathecal delivery involves injecting drugs directly into the cerebrospinal fluid (CSF) of the subarachnoid space, bypassing the BBB entirely. This approach delivers agents directly to the CNS, avoiding systemic exposure and first-pass metabolism. [@salvatore2006]
Spinraza (Nusinersen) — The landmark FDA-approved antisense oligonucleotide therapy for spinal muscular atrophy (SMA) demonstrates intrathecal delivery success. Spinraza is an ASO that alters SMN2 pre-mRNA splicing to increase production of functional SMN protein [1]. Administered via lumbar puncture into the CSF, it distributes throughout the CNS via diffusion through the interstitial space and perivascular channels. [@dhuria2010]
Delivering therapeutics to the central nervous system (CNS) remains one of the greatest challenges in neurodegeneration treatment. The blood-brain barrier (BBB) restricts approximately 98% of small molecule drugs and nearly all large molecule biologics from entering the brain parenchyma. This page provides a comprehensive overview of current and emerging CNS drug delivery strategies, their mechanisms, clinical applications, and future directions. [@finkel2017]
For detailed information on BBB biology and structure, see Blood-Brain Barrier Biology. [@mercuri2018]
Intrathecal delivery involves injecting drugs directly into the cerebrospinal fluid (CSF) of the subarachnoid space, bypassing the BBB entirely. This approach delivers agents directly to the CNS, avoiding systemic exposure and first-pass metabolism. [@salvatore2006]
Spinraza (Nusinersen) — The landmark FDA-approved antisense oligonucleotide therapy for spinal muscular atrophy (SMA) demonstrates intrathecal delivery success. Spinraza is an ASO that alters SMN2 pre-mRNA splicing to increase production of functional SMN protein [1]. Administered via lumbar puncture into the CSF, it distributes throughout the CNS via diffusion through the interstitial space and perivascular channels. [@dhuria2010]
nusinersen demonstrates that intrathecal delivery can achieve therapeutic effects in CNS disorders, validating this approach for other neurodegenerative diseases [2]. Clinical trials have explored intrathecal delivery for: [@lipsman2018]
| Advantage | Limitation | [@mudshingkar2022]
|-----------|------------| [@saraiva2016]
| Bypasses BBB completely | Invasive procedure (lumbar puncture) | [@niewoehner2014]
| High CNS concentrations | Distribution limited by diffusion | [@kariolis2020]
| Reduced systemic toxicity | Risk of infection or CSF leak | [@alvarezerviti2011]
| Direct targeting of spinal cord | Limited brain distribution | [@doxakis2023]
Intracerebroventricular delivery involves infusion directly into the cerebral ventricles, particularly the lateral ventricles. This approach provides broader CNS distribution than intrathecal delivery, reaching periventricular structures and cortical regions.
ICV delivery has been explored for [12]:
| Advantage | Limitation |
|-----------|------------|
| Broader CNS distribution than intrathecal | Requires neurosurgical implantation |
| Reaches cortical structures | Risk of infection, hemorrhage |
| Bypasses BBB | Risk of hydrocephalus |
| Continuous infusion possible | Device maintenance required |
Convection-enhanced delivery (CED) uses pressure-driven bulk flow to infuse drugs directly into brain tissue, achieving greater distribution volume than diffusion alone. A microcatheter is implanted stereotactically, and continuous infusion generates a pressure gradient that pushes therapeutic agents through the extracellular space.
CED has been investigated for [3,12]:
| Advantage | Limitation |
|-----------|------------|
| Large distribution volume | Requires surgical implantation |
| Precise targeting of specific brain regions | Backflow along catheter tract |
| Controlled, sustained infusion | Limited to ~1cm radius per catheter |
| Reduced systemic toxicity | Potential for tissue damage |
Intranasal delivery exploits the unique anatomy of the nasal cavity, where olfactory and trigeminal nerve pathways provide direct access to the CNS. This non-invasive approach allows drugs to bypass the BBB through:
Intranasal delivery has been explored for [4]:
| Advantage | Limitation |
|-----------|------------|
| Non-invasive, patient-friendly | Variable absorption |
| Rapid onset of action | Limited to small molecules/peptides |
| Bypasses BBB and first-pass metabolism | Nasal mucosa metabolism |
| Potential for self-administration | Not suitable for all drug types |
Focused ultrasound (FUS), particularly when combined with microbubbles, can temporarily and reversibly open the BBB. The mechanism involves:
Insightec ExAblate — The FDA-approved focused ultrasound device for essential tremor and Parkinson's disease tremor has been adapted for BBB opening in neurodegeneration trials.
Alzheimer's Disease Trials:
| Advantage | Limitation |
|-----------|------------|
| Non-invasive procedure | Requires specialized equipment |
| Transient, reversible BBB opening | Precise targeting required |
| Enhances antibody/macromolecule delivery | Potential for off-target effects |
| Can be repeated multiple times | Limited to accessible brain regions |
Nanoparticles provide versatile carriers for CNS drug delivery, offering advantages including:
Liposomes are phospholipid bilayer vesicles that can encapsulate both hydrophilic and hydrophobic drugs. Modern formulations include:
Biodegradable polymers (e.g., PLGA, PLA, PEG-PLA) provide controlled release and favorable safety profiles. Key considerations include:
Gold nanoparticles offer unique advantages:
Hyperbranched polymeric nanoparticles with:
Antibody shuttle systems exploit receptor-mediated transcytosis (RMT) to transport therapeutic payloads across the BBB. By engineering antibodies that bind to BBB-specific transporters, researchers can enable brain delivery of attached drugs.
Roche's Brain Shuttle technology uses an antibody fragment (scFv) specific to the transferrin receptor (TfR) to enable transcytosis. The system:
Denali Therapeutics developed the Transport Vehicle (TV) platform using:
Additional BBB-crossing technologies include:
| Advantage | Limitation |
|-----------|------------|
| Maintains antibody functionality | Requires engineering |
| Enables brain delivery of large molecules | Potential for immunogenicity |
| Can be combined with existing therapeutics | Competition with endogenous ligands |
| Modular, adaptable platform | Manufacturing complexity |
Exosomes are extracellular vesicles (30-150nm) that serve as natural intercellular communication vehicles. They can:
| Advantage | Description |
|-----------|-------------|
| Natural BBB penetration | Exosomes cross BBB more efficiently than synthetic nanoparticles |
| Cell-type targeting | Can be engineered with specific surface ligands |
| Low immunogenicity | Natural vesicles less likely to trigger immune responses |
| Cargo protection | Protect therapeutic cargo from degradation |
| Regulatory acceptance | Exosome therapeutics showing promise in clinical trials |
Exosome-based therapies in development include [10,11]:
Challenges in exosome-based delivery:
| Method | Invasiveness | BBB Bypass | Distribution | Clinical Status |
|--------|--------------|------------|--------------|-----------------|
| Intrathecal | Moderate | Yes | Spinal cord, limited brain | Approved (Spinraza) |
| ICV | High | Yes | Ventricular system, periventricular | Approved (enzyme replacement) |
| CED | High | Yes (direct infusion) | Local region | Clinical trials |
| Intranasal | Low | Yes (direct) | Limited, olfactory region | Clinical trials |
| Focused Ultrasound | Low | Temporary opening | Regional | Clinical trials |
| Nanoparticles | Low | Partial | Systemic, brain accumulation | Preclinical/clinical |
| Antibody Shuttles | Low | Yes (RMT) | Systemic | Clinical trials |
| Exosomes | Low | Yes | Variable | Early clinical |
The following diagram shows the key molecular relationships involving CNS Drug Delivery Methods discovered through SciDEX knowledge graph analysis: